Drug-induced movement disorders in children

Annals of the New York Academy of Sciences

Volumn 1142, Issue , 2008, Pages 72-84

  Gilbert, Donald L ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Antipsychotics; Bipolar disorder; Children; Dopamine receptor blocking medications; Dystonia; Iatrogenic disorders; Movement disorders; Psychotropic medications; Tardive dyskinesia; Tics

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BROMOCRIPTINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DANTROLENE; DIPHENHYDRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUPHENAZINE; HALOPERIDOL; METHYLPHENIDATE; METIROSINE; METOCLOPRAMIDE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PROCHLORPERAZINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RESERPINE; RISPERIDONE; TETRABENAZINE; UNINDEXED DRUG; ZIPRASIDONE;

AKATHISIA; ANTICHOLINERGIC EFFECT; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; BIPOLAR MANIA; CHILD HEALTH CARE; CHOREA; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITION; COGNITIVE THERAPY; DELIRIUM; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DIZZINESS; DOPAMINE RECEPTOR BLOCKING; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HEAT STROKE; HUMAN; HYDRATION; HYPERACTIVITY; HYPERKINESIA; HYPOTHERMIA; INSOMNIA; IRRITABILITY; MAJOR DEPRESSION; MALIGNANT HYPERTHERMIA; MEDICAL SPECIALIST; MENTAL DEFICIENCY; MOOD DISORDER; MORBIDITY; MOTOR DYSFUNCTION; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; OCULOGYRIC CRISIS; OFF LABEL DRUG USE; OROLINGUAL DYSKINESIA; PARKINSONISM; PATHOPHYSIOLOGY; PHENOMENOLOGY; PRESCRIPTION; PSYCHOSIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; TARDIVE DYSTONIA; TETANUS; THERMOREGULATION; TIC; TREATMENT PLANNING; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 54949102743     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1444.005     Document Type: Review

References (76)

1. Zito, J.M. et al. 2000. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283 : 1025 1030.
2. Cox, E.R. et al. 2003. Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics 111 : 237 243.
3. Rushton, J.L. & J.T. Whitmire. 2001. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998. Arch. Pediatr. Adolesc. Med. 155 : 560 565.
4. Delate, T. et al. 2004. Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. Psychiatr. Serv. 55 : 387 391.
5. Olfson, M. et al. 2006. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch. Gen. Psychiatry 63 : 679 685.
6. Goodwin, R. et al. 2001. Prescription of psychotropic medications to youths in office-based practice. Psychiatr. Serv. 52 : 1081 1087.
7. Carey, B. 2006. Use of antipsychotics by the young rose fivefold. New York Times. June 6, 2006.
8. Harris, G., B. Carey & J. Roberts. 2007. Psychiatrists, children and drug industry's role. New York Times. May 10, 2007.
9. Chapel, J.L., N. Brown & R.L. Jenkins. 1964. Tourette's disease: symptomatic relief with haloperidol. Am. J. Psychiatry 121 : 608 610.
10. Shapiro, E. et al. 1989. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch. Gen. Psychiatry 46 : 722 730.
11. Bruun, R.D. 1988. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder. Am. J. Psychiatry 145 : 621 624.
12. Silva, R.R. et al. 1996. Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. J. Clin. Psychiatry 57 : 129 135.
13. Sallee, F.R. et al. 1997. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am. J. Psychiatry 154 : 1057 1062.
14. Safer, D.J. 1997. Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s. J. Child Adolesc. Psychopharmacol. 7 : 267 274.
15. Patel, N.C., M.L. Crismon & A. Shafer. 2006. Diagnoses and antipsychotic treatment among youths in a public mental health system. Ann. Pharmacotherapy 40 : 205 211.
16. Patel, N.C. et al. 2005. Trends in the use of typical and atypical antipsychotics in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 44 : 548 556.
17. Safer, D.J. 2004. A comparison of risperidone-induced weight gain across the age span. J. Clin. Psychopharmacol. 24 : 429 436.
18. Moreno, C. et al. 2007. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch. Gen. Psychiatry 64 : 1032 1039.
19. Wonodi, I. et al. 2007. Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov. Disord. 22 : 1777 1782.
20. Laita, P. et al. 2007. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J. Child Adolesc. Psychopharmacol. 17 : 487 502.
21. Correll, C.U. 2007. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J. Am. Acad. Child Adolesc. Psychiatry 46 : 687 700.
22. Silva, R.R. et al. 1999. Neuroleptic malignant syndrome in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 38 : 187 194.
23. Fenn, D.S. et al. 1996. Movements in never-medicated schizophrenics: a preliminary study. Psychopharmacology 123 : 206 210.
24. Fenton, W.S. et al. 1997. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br. J. Psychiatry 171 : 265 268 Erratum in Br. J. Psychiatry 172: 97
25. Kurlan, R. et al. 2002. The behavioral spectrum of tic disorders: a community-based study. Neurology 59 : 414 420.
26. Kurlan, R. et al. 2001. Prevalence of tics in schoolchildren and association with placement in special education. Neurology 57 : 1383 1388.
27. Kurlan, R. et al. 1994. Tourette's syndrome in a special education population: a pilot study involving a single school district. Neurology 44 : 699 702.
28. Comings, D.E. & B.G. Comings. 1991. Clinical and genetic relationships between autism-pervasive developmental disorder and Tourette syndrome: a study of 19 cases. Am. J. Med. Genet. 39 : 180 191.
29. Ringman, J.M. & J. Jankovic. 2000. Occurrence of tics in Asperger's syndrome and autistic disorder. J. Child Neurol. 15 : 394 400.
30. Canitano, R. & G. Vivanti. 2007. Tics and Tourette syndrome in autism spectrum disorders. Autism 11 : 19 28.
31. Roesch-Ely, D. et al. 2006. Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia. Pharmacopsychiatry 39 : 115 116.
32. Liou, Y.-J. et al. 2004. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromol. Med. 5 : 243 251.
33. Gunes, A. et al. 2007. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology 190 : 479 484.
34. Plesnicar, B.K. et al. 2006. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J. Psychopharmacol. 20 : 829 833.
35. Segman, R.H. et al. 2000. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology 152 : 408 413.
36. Thomson Reuters. 2007. MICROMEDEX Health-care Series, DRUGDEX Drug Point 2008. Thomson Reuters Healthcare. Available at http://www.thomsonreuters.com/ business_units/healthcare/ or http://www.micromedex.com/index.html.
37. Gilbert, D.L. & C.R. Buncher. 2005. Assessment of scientific and ethical issues in two randomized clinical trial designs for patients with Tourette's syndrome: a model for studies of multiple neuropsychiatric diagnoses. J. Neuropsychiatry Clin. Neurosci. 17 : 324 332.
38. Cassady, S.L. et al. 1997. The Maryland psychiatric research center scale and the characterization of involuntary movements. Psychiatry Res. 70 : 21 37.
39. Guy, W. 1976. ECDEU Assessment Manual for Psychopharmacology. United States Department of Health, Education, and Welfare. Rockville, MD.
40. Tammenmaa, I.A. et al. 2002. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. Issue 2, Art. No. CD000207. Available at http://www.cochrane.org/reviews/en/ab000207. html. DOI :.
41. Soares-Weiser, K. & J. Rathbone. 2005. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst. Rev. Issue 3, Art. No. CD000459. Available at http://www.cochrane.org/reviews/en/ab000459.html. DOI :.
42. Ankenman, R. & M.F. Salvatore. 2007. Low dose alpha-methyl-para- tyrosine (AMPT) in the treatment of dystonia and dyskinesia. J. Neuropsychiatry Clin. Neurosci. 19 : 65 69.
43. Soares-Weiser, K.V. et al. 2003. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. Issue 1, Art. No. CD000208. Available at http://www.cochrane.org/reviews/en/ab000208. html. DOI :.
44. Soares, K.V.S. & J.J. McGrath. 2001. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. Issue 3, Art. No. CD000209. Available at http://www.cochrane.org/reviews/en/ab000209. html. DOI :.
45. Soares-Weiser, K. & J. Rathbone. 2003. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. Issue 4, Art. No. CD000206. Available at http://www.cochrane.org/reviews/en/ab000206. html. DOI :.
46. Zuvekas, S.H., B. Vitiello & G.S. Norquist. 2006. Recent trends in stimulant medication use among U.S. children. Am. J. Psychiatry 163 : 579 585.
47. Swanson, J. et al. 2006. Stimulant-related reductions of growth rates in the PATS. J. Am. Acad. Child Adolesc. Psychiatry. 45 : 1304 1313.
48. Greenhill, L. et al. 2006. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J. Am. Acad. Child Adolesc. Psychiatry. 45 : 1284 1293 Erratum in J. Am. Acad. Child Adolesc. Psychiatry 46: 141 et al. 2001. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108 : E83.
49. Lowe, T.L. et al. 1982. Stimulant medications precipitate Tourette's syndrome. JAMA 247 : 1729 1731.
50. Scahill, L. et al. 2006. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 3 : 192 206.
51. Tourette Syndrome Study Group. 2002. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58 : 527 536.
52. Denckla, M.B. & R.G. Rudel. 1978. Anomalies of motor development in hyperactive boys. Ann. Neurol. 3 : 231 233.
53. Mostofsky, S.H., C.J. Newschaffer & M.B. Denckla. 2003. Overflow movements predict impaired response inhibition in children with ADHD. Percept. Mot. Skills 97 : 1315 1331.
54. Eapen, V. et al. 1997. Gilles de la Tourette's syndrome in special education schools: a United Kingdom study. J. Neurol. 244 : 378 382.
55. Kurlan, R. 1994. Hypothesis II: Tourette's syndrome is part of a clinical spectrum that includes normal brain development. Arch. Neurol. 51 : 1145 1150.
56. Bodfish, J.W. et al. 1996. Dyskinetic movement disorder among adults with mental retardation: phenomenology and co-occurrence with stereotypy. Am. J. Ment. Retard. 101 : 118 129.
57. Mahone, E.M. et al. 2004. Repetitive arm and hand movements (complex motor stereotypies) in children. J. Pediatr. 145 : 391 395.
58. Multimodal Treatment of ADHD Cooperative Group. 1999. A 14-month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder. Multimodal treatment study of children with ADHD. Arch. Gen. Psychiatry 56 : 1073 1086.
59. Molina, B.S. et al. 2007. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J. Am. Acad. Child Adolesc. Psychiatry 46 : 1028 1040.
60. Wigal, T. et al. 2006. Safety and tolerability of methylphenidate in preschool children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 45 : 1294 1303.
61. Gilbert, D.L. et al. 2003. Tic reduction with pergolide in a randomized controlled trial in children. Neurology 60 : 606 611.
62. Zanettini, R. et al. 2007. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356 : 39 46.
63. Allen, A.J. et al. 2005. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 65 : 1941 1949.
64. Bond, G.R., A.C. Garro & D.L. Gilbert. 2007. Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clin. Toxicol. (Phila) 45 : 182 185.
65. Gilbert, D.L. 2006. Treatment of children and adolescents with tics and Tourette syndrome. J. Child Neurol. 21 : 690 700.
66. Boyer, E.W. & M. Shannon. 2005. The serotonin syndrome. N. Engl. J. Med. 352 : 1112 1120.
67. McKeon, A. et al. 2007. Whole-body tremulousness: isolated generalized polymyoclonus. Arch. Neurol. 64 : 1318 1322.
68. Sokolski, K.N., A. Chicz-Demet & E.M. Demet. 2004. Selective serotonin reuptake inhibitor-related extrapyramidal symptoms in autistic children: a case series. J. Child Adolesc. Psychopharmacol. 14 : 143 147.
69. Spirko, B.A. & J.F. Wiley, 2nd. 1999. Serotonin syndrome: a new pediatric intoxication. Pediatr. Emerg. Care 15 : 440 443.
70. Pediatric OCD Treatment Study (POTS) Team. 2004. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the pediatric OCD treatment study (POTS) randomized controlled trial. JAMA 292 : 1969 1976.
71. Murphy, J.M., R. Motiwala & O. Devinsky. 1991. Phenytoin intoxication. South. Med. J. 84 : 1199 1204.
72. Patsalos, P.N. & E. Perucca. 2003. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2 : 473 481.
73. Sotero de Menezes, M.A. et al. 2000. Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia 41 : 862 867.
74. Giles, L.L. et al. 2008. Cerebellar ataxia in youth at risk for bipolar disorder. Bipolar Disorders. In Press.
75. Flynn, L. et al. 1997. Measuring treatment effectiveness. Part one: Newly emerging outcomes databases for organizations. Behav. Healthc. Tomorrow 6 : 37 44.
76. Kramer, E.D. et al. 1997. Acute neurologic dysfunction associated with high-dose chemotherapy and autologous bone marrow rescue for primary malignant brain tumors. Pediatr. Neurosurg. 27 : 230 237.